T. Andrew Crockett – Chief Executive Officer
Andrew is a co-founder of KalVista Pharmaceuticals and it's CEO. Prior to KalVista, Andrew held various senior management positions including chief executive, vice president of business development and director of clinical and regulatory affairs in biotech and specialty pharmaceutical companies in the United States and United Kingdom. During his career he has identified, negotiated and executed strategic corporate transactions on a global basis, including mergers and acquisitions, national and international product licenses, IP and technology licenses, and R&D alliances.
Andrew received a BA from the University of Utah, and an MBA from The Wharton School, University of Pennsylvania, with a major in Finance.
Edward P. Feener, PhD - Chief Scientific Officer
Ed is a co-founder of KalVista and joined as Chief Scientific Officer in 2016. Previously, Dr. Feener was an Associate Professor of Medicine at Harvard Medical School and Senior Investigator in the Section on Vascular Cell Biology at Joslin Diabetes Center. He has 30 years of research experience in vascular biology and diabetic complications. His laboratory has performed pioneering research on the kallikrein kinin system and was first to identify plasma kallikrein as a potential therapeutic target for diabetic macular edema. Ed has published over 80 scientific articles and has served on multiple national and international scientific research review committees.
Ed received his PhD in Biochemistry from Boston University and completed postdoctoral training at the Joslin Diabetes Center and Harvard Medical School.
Andreas Maetzel, MD, PhD - Senior Vice President Medical
Andreas joined KalVista as Senior Vice President of Medical in March 2017. Dr. Maetzel was most recently Vice President, Global Medical Affairs at BioCryst Pharmaceuticals. Prior to that he was Vice President, Clinical Development & Regulatory Affairs at Cornerstone Therapeutics Inc. Previously, Dr. Maetzel held a clinical development role at BioCryst, and also positions in strategy consulting and health technology assessment strategy at Amgen.
He is a Visiting Scientist at the University Hospital Zurich and Charité Hospital Berlin, and maintains an appointment as Adjunct Professor, Institute for Health Policy, Management & Evaluation, University of Toronto. Dr. Maetzel obtained both a PhD and MSc in Clinical Epidemiology from the University of Toronto and a Dr.med at the University of Hannover, Germany.
Benjamin L. Palleiko – Chief Financial Officer
Ben joined KalVista as Chief Financial Officer in August 2016. He has over 20 years of industry experience as a life sciences investment banker at firms including Robertson Stephens and SunTrust, and a senior executive of several public and private biotech companies including SVP & CFO of Ore Pharmaceutical Holdings and Penwest Pharmaceuticals Co. In his roles Ben has overseen strategic planning, business development, business operations, finance, human resources, legal, and investor relations. He has completed over 50 strategic, licensing, and financing transactions and raised more than $2 billion in capital.
Ben holds a BA in Quantitative Economics from Tufts University, and an MBA in Finance and MA in International Relations from the University of Chicago. He served as a Naval Aviator in the U.S. Navy.
Christopher M. Yea, PhD - Chief Development Officer
Chris holds a BSc and PhD in Biochemistry from the University of Bristol, UK. Following post-doctoral work he spent several years at Roussel-UCLAF and Hoechst Marion Roussel before joining Ferring Pharmaceuticals. Chris led the Biology group and was responsible for transition of candidates into development. In 2008, Chris co-led the spin-out of Vantia Ltd and most recently was Chief Operating Officer where he was responsible for development activities through Phase 3 trials.
In his position as Chief Development Officer, Chris is responsible for all development-related activities within KalVista Pharmaceuticals.